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INTRODUCTION
Systemic lupus erythematosus (SLE)
is a systemic autoimmune disease, char-
acterized by the involvement of many
organs and the presence of autoantibod-
ies directed to nuclear and cytoplasmic
antigens. The pathogenesis is unknown;
it is assumed that a disturbed clearance
of apoptotic cells plays a central role.
Several lines of evidence support that
accumulation of apoptotic cells is instru-
mental in the development of SLE. In
several animal models, deficiency of
proteins such as complement factor C1q
and serum amyloid P component (SAP),
which are involved in opsonization and
thereby phagocytosis and clearance of
apoptotic cells, results in spontaneous
development of lupuslike features, in-
cluding production of autoantibodies
and proliferative glomerulonephritis
(1,2). Furthermore, injection of apoptotic
cells result in development of SLE-like
disease (3). Also in human SLE, accu-
mulation of apoptotic cells has been
found. In peripheral blood, increased
levels of apoptotic lymphocytes (4) and
neutrophils (5) have been demonstrated.
Moreover, in lymph nodes from lupus
patients apoptotic lymphocytes are
present (6). In the skin of lupus patients,
after UVB irradiation, in comparison to
healthy controls, apoptotic cells accu-
mulate. Importantly, in the vicinity of
these cells, inflammatory lesions oc-
curred (7). Apoptotic cells express anti-
gens on their cell surface that serve as
targets of the autoimmune response that
is typical of the disease, in part because
these antigens may undergo posttrans-
lational modifications during the pro-
cess of apoptosis.
Moreover, when apoptotic cells are
not cleared, these cells turn into necrotic
cells that lose their membrane integrity,
thereby releasing intracellular structures
that can act as autoantigens. In this con-
text, nucleosomes, bound to the nuclear
protein high-mobility group box 1
(HMGB1), were shown to induce not
only immune, but also inflammatory re-
sponses that are relevant for the patho-
genesis of SLE (8). In this review, after a
short summary of HMGB1 functions, we
will discuss the (potential) contribution
of HMGB1 in the different stages SLE
development.
HMGB1
HMGB1 is a nonhistone nuclear pro-
tein that has several functions, depend-
ing on its location and posttranslational
modifications. HMGB1 is a highly con-
served protein of 215 amino acids that is
ubiquitously expressed in nuclei where it
binds to DNA. The protein can be di-
vided into three separate domains: the A
box, B box and acidic tail. Box A serves
as a competitive antagonist for HMGB1
and inhibits HMGB1 activity. Both A and
B box are important for its DNA binding
functions and are positively charged,
whereas the tail is negatively charged,
giving the molecule a bipolar charge.
HMGB1 is important in several DNA-
 related biological processes, reflected by
the fact that HMGB1 can bend promoter
regions and can interact directly with nu-
cleosomes, thereby altering the accessi-
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bility of the DNA (9). The importance of
HMGB1 was demonstrated by the fact
that mice deficient for the protein die
within 24 h after birth because of severe
hypoglycemia. In contrast, fibroblast cell
lines, derived from the same HMGB1–/–
mice, can proliferate and survive, indi-
cating that the effects might be cell spe-
cific (10).
HMGB1 can be released from the cell
into the extracellular space, where it acts
as a damage-associated molecular pat-
tern (DAMP) or alarmin. Translocation
from the nucleus to the cytoplasm oc-
curs through acetylation of lysine
residues, where the protein is concen-
trated in vesicles for secretion (11,12).
The extracellular release of HMGB1 can
occur either passively or actively by se-
cretion. More importantly, the manner of
release determines posttranslational
modifications of released HMGB1. Pas-
sive release of HMGB1 usually results
from leakage due to damaged cell mem-
branes. Active release by secretion oc-
curs when immune cells are exposed to,
for instance, pathogen-associated molec-
ular patterns (PAMPs), tumor necrosis
factor (TNF)-α or lipopolysaccharide
(LPS) via nonclassical pathways. When
present in extracellular space, HMGB1
exerts several functions, including cy-
tokine release by monocytes (13–16), cell
migration (17), wound healing (18) and
neovascularization (19).
INTERACTION WITH RECEPTORS: REDOX
STATUS OF HMGB1
Extracellular HMGB1 can bind to sev-
eral receptors, including toll-like recep-
tor (TLR)-2, -4 and -9; receptor for ad-
vanced glycation end products (RAGE)
and chemokine receptor C-X-C motif re-
ceptor 4 (CXCR4) (17,20,21). RAGE, both
in soluble and membrane form, was the
first receptor demonstrated to bind
HMGB1. RAGE is a transmembrane,
multiligand member of the immunoglob-
ulin superfamily expressed on mono-
cytes, macrophages and other cells (22).
Binding of HMGB1 to RAGE initiates
cell migration–dependent pathways via
nuclear factor-κB activation (23,24).
Moreover, cell migration can also occur
when HMGB1 is complexed to
chemokine CXCL12, and then it acts
synergistically through CXCR4 (17,25).
Recently, binding of HMGB1 to its re-
ceptors was shown to be related to the
different redox states of HMGB1. Several
studies showed that when a disulfide
bridge exists between cysteines C23 and
C45, and cysteine C106 is in a thiol (re-
duced) state, HMGB1 exerts cytokine-
 inducing properties via binding to TLR4
(25–27). Adding this cytokine HMGB1 to
RAW 264.7 macrophages induced expres-
sion and release of TNF, whereas com-
pletely reduced HMGB1, which can be
produced in the presence of dithiotreitol
(DTT), did not (25–27). HMGB1 has
chemoattractant properties when all
three cysteines are reduced. By using a
migration assay, mouse fibroblasts mi-
grated toward increasing concentrations
of all-thiol HMGB1 (17,25). Moreover, it
was shown that the cytokine and
chemoattractant properties of HMGB1
are mutually exclusive because of these
different redox statuses of HMGB1: all-
thiol HMGB1 failed to induce cytokine
production, while disulfide HMGB1 did
not attract mouse fibroblasts (25). When
HMGB1 is released from apoptotic cells,
it induces immunogenic tolerance and
has no chemotactic properties, since its
three cysteines are terminally oxidized
by reactive oxygen species to sulfonates
(11,25,27). However, when HMGB1 is re-
leased from necrotic cells, it still has in-
flammatory properties, as shown by the
fact that necrotic HeLa HMGB1–/– cells
do not induce TNF production in mono-
cytes, whereas wild-type cells could in-
duce TNF (12).
COMPLEXED FORMS OF HMGB1
Next to binding to CXCL12, as described
before, HMGB1 forms complexes with sev-
eral other molecules, including LPS, inter-
leukin (IL)-1, —C—phosphate—G— (CpG),
double-stranded DNA and nucleosomes.
 Hreggvidsdottir et al. (28) showed that
HMGB1 forms highly immunostimulatory
complexes with LPS and Pam3CSK4,
thereby increasing response in macro-
phages up to 100-fold. These authors fur-
thermore showed that signaling of these
complexes was primarily done by TLR4
and TLR2 and not by additional signaling
cascades. In SLE, formation of many im-
mune complexes is well described, and it
has been shown that HMGB1 bound in
these complexes is present in plasma and
serum of SLE patients (29–31). Tian et al.
(29) showed that HMGB1 bound to CpG
motifs induced cytokine production by in-
teracting with RAGE and not TLR2 or
TLR4. Moreover, they showed that a mon-
oclonal antibody to HMGB1 significantly
reduced interferon (IFN)-α production in
peripheral blood mononucleated cells
stimulated with plasma from lupus pa-
tients containing HMGB1-CpG complexes
(29). HMGB1 complexes were also impli-
cated in the pathogenesis of lupus nephri-
tis. Qing et al. (32) showed that the patho-
genic anti-DNA antibody 1A3F could
bind to HMGB1 and HMGB1-DNA com-
plexes. HMGB1 and 1A3F exhibited a
synergistic proinflammatory effect in the
kidney, where increased expression of
HMGB1 was found in lupus patients but
not in patients with other types of renal
disease. They concluded that HMGB1
may act as a proinflammatory mediator in
antibody-induced kidney damage in SLE.
More recently, it was shown that HMGB1
has a role in autoantibody induction itself.
In SLE patients, circulating DNA-
 containing immune complexes induced
anti-dsDNA antibodies. Importantly,
HMGB1 in circulating DNA-containing
immunocomplexes was crucial for anti-
dsDNA antibody induction (31). By using
box A to block the effect of HMGB1, the
production of anti-dsDNA antibodies was
abrogated in a dose-dependent manner,
whereas adding HMGB1 to the culture
system increased production of anti-
dsDNA antibodies (31). However, unlike
the previous study by Tian et al. (29), here
it was shown that the effect was solely
mediated through TLR2 and MyD88. The
data in this study are in line with the re-
sults found by  Urbonaviciute et al. (30),
who showed that injecting HMGB1-
 nucleosome complexes induced anti-
dsDNA production through TLR2 in
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BALB/c mice. Furthermore, incubating
human monocyte-derived macrophages
with HMGB1-nucleosome complexes in-
duced cytokine production, which could
be blocked by adding box A. Whereas
these studies focused on effects of
HMGB1 on lymphocytes, Sun et al. (33)
investigated the effect of HMGB1-contain-
ing immune complexes on human en-
dothelial cells. They showed that stimu-
lating endothelial cells with immune
complexes from SLE patients increased
proinflammatory cytokines such as IL-6
and IL-8. Furthermore, RAGE, vascular
cell adhesion molecule (VCAM)-1 and in-
ducible cell adhesion molecule (ICAM)-1
showed higher expression on the cell sur-
face. These effects could be blocked by
adding box A or soluble RAGE, indicating
that HMGB1 plays an important role in
mediating inflammation in endothelial
cells. Taken together, these studies show
that HMGB1 mediates several roles by
acting in immune complexes, depending
on the effector cells and components that
are present in these complexes.
HMGB1 AND PHAGOCYTOSIS
Phagocytosis (or efferocytosis) is an
important mechanism that enables in-
nate immune cells to clear cell debris
and ingest microbes. Impaired phagocy-
tosis of apoptotic debris has been impli-
cated in SLE pathogenesis and leads to
secondary cell necrosis and exposition of
intracellular contents of the necrotic cells
to the surrounding tissue, which in turn
can induce a proinflammatory response
(34). Serum factors, such as complement,
are important for an effective phagocy-
totic response and were found to be de-
creased in SLE patients (35). HMGB1 has
been described to be a factor that can
contribute to a decrease in phagocytosis.
In a series of articles by Abraham and
colleagues, it was shown that HMGB1
has a negative effect on phagocytosis via
different mechanisms (36–38). First, it
was shown that HMGB1 can bind to
phosphatidylserine (PS) present on the
surface of apoptotic neutrophils. The
presence of PS on the outer leaflet of
cells is one of the most important “eat
me” signals for macrophages. Accord-
ingly, efferocytosis was inhibited when
HMGB1 masked PS (36). Next, it was
shown that when macrophages were
pre-incubated with HMGB1, their ability
to engulf apoptotic neutrophils and thy-
mocytes was decreased. HMGB1 com-
peted with the opsonin milk fat globule
epidermal growth factor 8 (MFG-E8) for
binding to integrin αvβ3, a receptor im-
portant in recognizing PS. MFG-E8 was
shown to act as a bridge between PS and
to integrin αvβ3, thereby enhancing effe-
rocytosis (37). RAGE-deficient macro-
phages were shown to have a dimin-
ished capacity to phagocytose, and the
inhibitory effect of HMGB1 on phagocy-
tosis was contributed to the C-terminal
tail of the protein. When the C-terminus
was eliminated, the inhibitory effect of
HMGB1 was greatly diminished, attrib-
uted to the fact that HMGB1 was not
able to bind to RAGE in vitro and in vivo
(38). Moreover, it was shown that
PARPylation of HMGB1 by PARP-1
[poly(ADP)-ribose polymerase] en-
hanced the capacity of HMGB1 to inhibit
efferocytosis, indicating that posttransla-
tional modifications of HMGB1 play a
role. PARP-1 was implicated in inflam-
mation, and activation of PARP-1 in-
duces migration of HMGB1 from the nu-
cleus to the cytoplasm. It was shown
that after stimulation of TLR4, PARPy-
lated HMGB1 was secreted, which could
inhibit efferocytosis more efficiently than
non-PARPylated HMGB1 by enhanced
binding to PS and RAGE (39). Lastly, it
was shown that intracellular HMGB1
also diminishes the phagocytosis by
macrophages through interactions with
Src and focal adhesion kinase (FAK).
Knockdown of intracellular HMGB1 by
siRNA increased phagocytosis and cy-
toskeletal rearrangement, in which FAK
plays an important role (40). As HMGB1
serum levels are increased in SLE pa-
tients (which will be discussed later on),
it seems logical that serum HMGB1 can
contribute to the impaired phagocytosis
described in SLE patients. However, at
this moment, there are no reports that
address this issue.
HMGB1 AND NETS
In addition to apoptosis and necrosis,
a new form of cell death was described
in 2004 by Brinkmann et al. (41). They
showed that neutrophils can entrap mi-
croorganisms by a programmed external-
ization of chromatin fibers decorated
with antimicrobial proteins derived from
granules. This process was called neu-
trophil extracellular trap (NET) forma-
tion or NETosis, and the processes in-
volved leading to NETosis were
investigated in detail (42). The first link
between NETosis and autoimmunity was
observed in small vessel vasculitis,
where it was shown that NETs external-
ize the autoantigens proteinase 3 (PR3)
and myeloperoxidase (MPO) and that
antineutrophil cytoplasmic antibodies
(ANCAs) induce NETosis (43). In 2011,
enhanced NETosis in SLE patients was
described (44–46). Normally, NETs are
degraded by DNase-1 in the circulation,
but the ability to reduce NETs is dimin-
ished in SLE patients and is associated
with disease activity (47). Villanueva et
al. (46) showed that low-density granulo-
cytes spontaneously can form NETs.
Low-density granulocytes are a neu-
trophil subset that can be found in the
mononuclear cell fraction, and they have
been reported to be present in all SLE pa-
tients (48). Comparing gene array pro-
files of low-density granulocytes to nor-
mal density neutrophils showed that
low-density granulocytes significantly
overexpressed mRNA of various im-
munostimulatory bactericidal proteins
and alarmins, relative to lupus neu-
trophils and control neutrophils.
Next to spontaneous NET formation
in SLE patients, it was shown that 
autoantibodies such as anti-RNP (anti-
 ribonucleoprotein) or immunogenic com-
plexes composed of neutrophil-derived
antimicrobial peptides and self-DNA can
induce NETosis (44,45). NETs can stimu-
late plasmacytoid dendritic cells to pro-
duce type I interferon (IFN-α), which has
an important role in pathogenesis of SLE
(44–46). NETs contain DNA and much
HMGB1 and LL37, a cationic antimicro-
bial peptide that converts self-DNA and
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self-RNA into TLR activators (44). These
neutrophil proteins facilitate the uptake
and recognition of mammalian DNA by
plasmacytoid dendritic cells. Next to
being excreted by neutrophils, HMGB1
also induces NETosis in neutrophils by
interaction through TLR4 but not
through RAGE (49). This result has not
been confirmed by other studies until
now and has not been investigated in
neutrophils from SLE patients.
HMGB1 IN SLE PATIENTS AND OTHER
RHEUMATIC DISEASES
Different groups have shown that
HMGB1 levels are elevated in serum and
plasma samples from patients with SLE
(50–54). In addition, it was shown that
HMGB1 correlated with the SLE Disease
Activity Index (SLEDAI) and anti-
dsDNA, whereas there was an inverse
correlation with complement C3 (50,55).
An important feature of SLE is the pro-
duction of autoantibodies against several
different nuclear and cytoplasmic pro-
teins. Indeed, also antibodies to HMGB1
were found in SLE, which seems specific
to the disease, since these antibodies
were not found in patients with systemic
vasculitis (50,56,57). Interference of these
antibodies with detection of serum
HMGB1 by enzyme-linked immunosor-
bent assay (ELISA) was noted (50,58),
and it seems that the best way to detect
HMGB1 in the serum of SLE patients is
by immunoblot. The presence of anti-
HMGB1 antibodies correlates with serum
HMGB1, SLEDAI and anti-dsDNA anti-
bodies (50), indicating that these antibod-
ies might have a pathogenic role. In sep-
sis, however, a protective role of
anti-HMGB1 antibodies was found (59),
initiating a debate about the role of these
antibodies. Epitope mapping of the anti-
HMGB1 antibodies revealed that the ma-
jority of the antibodies reacted against
box A (56), indicating that box A is not a
treatment option for SLE. It might be ex-
pected that box A in lupus will be neu-
tralized. In contrast, in animal models in
other diseases in which anti-HMGB1 an-
tibodies are not present, such as sepsis,
administration of box A is beneficial (60).
In several other autoimmune diseases,
such as Sjögren syndrome, juvenile
arthritis and rheumatoid arthritis, it was
documented that serum levels of
HMGB1 are increased in patients com-
pared with healthy controls, showing
that increased HMGB1 levels are not a
specific feature of SLE (61–65) (Table 1).
Wibisono et al. (66) investigated HMGB1
levels in patients with ANCA-associated
vasculitis (AAV), and they found signifi-
cant increased HMGB1 levels in patients
with active granulomatosus with
polyangiitis (GPA), but not in patients
with microscopic polyangiitis (MPA).
These data were confirmed by Bruchfeld
et al. (67), who also found increased
HMGB1 levels in GPA patients with
renal involvement, and by Henes et al.
(68), who showed a correlation between
HMGB1 and the burden of granuloma-
tous inflammation. Recently, however,
HMGB1 was described not to be a useful
biomarker in AAV, because HMGB1 lev-
els were not associated with an in-
creased risk for relapse in AAV (57). In
ankylosing spondylitis patients, HMGB1
levels were reported slightly elevated
compared with healthy controls as well
(69). Importantly, when comparing
amounts of HMGB1 in serum in these
different rheumatic diseases, levels are
moderately increased compared with
healthy controls (Table 1). In contrast,
we found in 33 quiescent SLE patients
(SLEDAI <4), with low amounts of anti-
HMGB1, an average level of HMGB1 of
6.2 ng/mL (range 1.3–32.3) measured by
ELISA (50). As mentioned before, ELISA
is not suitable for measuring HMGB1 in
active SLE patients, but from these data,
it is suggested that active SLE patients
will have much higher amounts of
HMGB1 in their serum. Recently in-
creased HMGB1 levels were reported in
juvenile SLE patients (70).
As mentioned above, redox status
plays an important role in HMGB1 func-
tionality. Until now, one report has inves-
tigated the redox status of HMGB1 in
serum of SLE patients. It was shown that
oxidized HMGB1 is present in these
serum samples. However, this study in-
cluded only a small number of patients
with severe disease activity (71). More re-
search is needed in larger patient groups
with different disease activity to investi-
gate which isoforms of HMGB1 are pres-
ent in serum of SLE patients.
HMGB1 AND LUPUS NEPHRITIS
In patients with renal involvement,
higher HMGB1 levels were observed in
serum compared with patients without
renal involvement (50,52). In kidney
biopsies of patients with lupus nephritis,
cytoplasmic and extracellular HMGB1
was found (54,55), which was not present
in control tissue. Furthermore, HMGB1
was detectable in urine of patients with
lupus nephritis, but not in healthy con-
trols, and correlated positively with
serum HMGB1, proteinuria and SLEDAI
and inversely with complement C3 lev-
els. Strong expression levels of the recep-
tors for HMGB1 (RAGE, TLR2 and TLR4)
were seen in kidney tissue from patients
with active lupus nephritis, indicating
that HMGB1 can exert it functions (55).
These studies suggest that HMGB1 might
serve as a marker of disease activity in
SLE patients, especially in those with
renal  involvement.
HMGB1 AND CUTANEOUS LUPUS
Research on the effects of ultraviolet ir-
radiation on the skin of lupus patients
showed that exposure to ultraviolet light
induces apoptosis of keratinocytes and
the release of proinflammatory cytokines
(72). In susceptible patients, the presence
or even accumulation of apoptotic cells
after ultraviolet exposure results in the
induction of characteristic inflammatory
skin lesions, which might be due to a de-
layed and proinflammatory clearance of
these apoptotic cells. A few studies ana-
lyzed the presence of HMGB1 in the skin
of patients with cutaneous lupus. A
higher expression of cytoplasmic and ex-
tracellular HMGB1 was observed in le-
sional skin of lupus patients. Extracellu-
lar HMGB1 was only observed in lesional
skin and not in healthy subjects (73).
Moreover, in experimentally photo-pro-
voked lesions, the number of HMGB1-
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Table 1. Serum HMGB1 levels in different rheumatic diseases.
Number 
of Detection
Disease patients Disease state HMGB1 level method Reference
SLE
20 Lupus nephritis 108 ng/mL (19.8–202.4) WB Zickert et al. (54)
HC: 13 ± 10 ng/mL
33 Inactive 6.2 ng/mL (1.3–32.3) ELISA (Shino/IBL) Abdulahad et al. (50)
HC: 2.9 ng/mL (0–7.7)
51 AU (28–121) WB
37 Active 135 AU (81-496) WB
HC: 43 AU (7–85)
11 Inactive 4.12 ± 1.97 ng/mL ELISA (Shino/IBL) Ma et al. (53)
26 Active 6.44 ± 4.18 ng/mL
HC: 4.45 ± 1.59
Juvenile SLE
26 Inactive 30 ± 5.28 ng/mL ELISA (Amsbio) Kanakoudi-Tsakalidou et al. (70)
Active 17.98 ± 3.2 ng/mL
HC: 1.38 ± 0.23 ng/mL
Vasculitis
46 GPA inactive 11.63 ± 8.8 ng/mL ELISA (Shino/IBL) Wibisono (66)
active 4.89 ± 3.37 ng/mL
44 MPA inactive 2.61 ± 2.5 ng/mL
active 2.61 ± 2.7 ng/mL
HC: 3.0 ± 2.8 ng/mL
169 GPA 4.68 ± 3.66 ng/mL ELISA (Shino/IBL) Henes et al. (68)
HC: 2.34 ± 2.01 ng/mL
30 GPA inactive 78 ± 46 ng/mL WB Bruchfeld et al. (67)
active 120 ± 48 ng/mL
HC: approx. 10 ng/mL
33 GPA 2.66 1.83 ng/mL ELISA (Shino/IBL) de Souza et al. (57)
11 MPA 3.11 ± 1.91 ng/mL
8 Renal limited vasculitis 1.92 ± 1.48 ng/mL
HC: 2.39 ± 1.09 ng/mL
Rheumatoid arthritis
30 1.5 ± 4.2 ng/mL WB Taniguchi et al. (65)
No HC
13 71 ng/mL (45–99) WB Goldstein (62)
HC: 18 ng/mL (0-40)




23 Equal to HC ELISA (Shino/IBL) Schierbeck et al. (64)
Sjögren syndrome
101 1.79 ng/mL (0.25–3.35) ELISA (unsp) Dupire et al. (61)
HC: 1.46 ng/mL (0.94–1.74)
Ankylosing spondylitis
30 0.86 ± 0.37 ng/mL ELISA (USCN) Oktayoglu et al. (69)
HC: 0.65 ± 0.39
Data are means ± standard deviation or median (range). AU, arbitrary units; HC, healthy controls; WB, Western blot.
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negative cells increased, and cytoplasmic
HMGB1 was significantly more present
in active lesions (74). These two studies,
however, only used skin of patients who
were photosensitive, whereas the study
by our group also investigated the role of
HMGB1 in skin of lupus patients, irre-
spective of having a history of photosen-
sitivity (75). After irradiation, the number
of negative nuclei indicating transloca-
tion of HMGB1 to the cytoplasm signifi-
cantly increased in patients compared
with healthy controls. In patients, there
was also a significant correlation between
the presence of apoptotic keratinocytes,
also called sunburn cells, and HMGB1-
negative nuclei. Moreover, in patients,
there was a significantly higher influx of
inflammatory cells compared with
healthy controls, but there was no corre-
lation with number of negative nuclei, in-
dicating released HMGB1. Together, these
studies show that HMGB1 plays a proin-
flammatory role in cutaneous lupus.
INTERVENTION/FUTURE
HMGB1, as has been shown in this re-
view, plays an important role as an in-
flammatory mediator in SLE and can act
alone or in complex with several other
molecules. In Figure 1 the role of HMGB1
in SLE is depicted. Currently, most stud-
ies have focused on observations that
HMGB1 is increased in lupus patients, ei-
ther in serum, urine, kidney or skin. To
our knowledge, there are no intervention
studies blocking the effects of HMGB1 in
lupus animal models or in SLE patients.
Several different animal models of (auto-
immune) disease use blocking agents,
such as box A or neutralizing antibodies
against HMGB1 to alleviate symptoms of
disease (60). Because of the increase of
HMGB1 in serum of SLE patients, this
seems to be an appealing option. How-
ever, because anti-HMGB1 antibodies are
present in sera from SLE patients that rec-
ognize box A, these two treatments do
not seem like a feasible option for SLE. In
animal models, other interventions have
been tested, such as small interference
RNA (siRNA), metformin (an antidiabetic
drug) and glycyrrhizin, a small molecule
that can bind directly to HMGB1 (60).
Most work has been done in LPS-
 mediated mice models or sepsis models,
and more research is needed to translate
these findings to autoimmunity and SLE
specifically.
Exploring the mechanisms behind
HMGB1-induced inflammation in SLE is
needed, since there is still much un-
known. Much knowledge about
HMGB1 biology has already been
amassed by in vitro studies that investi-
gate the pathways, receptors and post-
translational modifications; however,
most of the studies have not been trans-
lated to disease models. Future studies,
in lupus animal models and in SLE pa-
tients, should focus on delineating the
kinetics, cellular location and redox sta-
tus of HMGB1.
DISCLOSURE
The authors declare that they have no
competing interests as defined by Molecu-
lar Medicine, or other interests that might
be perceived to influence the results and
discussion reported in this paper. 
REFERENCES
1. Bickerstaff MC, et al. (1999) Serum amyloid P com-
ponent controls chromatin degradation and pre-
vents antinuclear autoimmunity. Nat. Med. 5:694–7.
2. Botto M, et al. (1998) Homozygous C1q defi-
ciency causes glomerulonephritis associated with
multiple apoptotic bodies. Nat. Genet. 19:56–9.
Figure 1. Role of HMGB1 in pathogenesis of SLE. In SLE, release of HMGB1 can occur via
different routes: first, HMGB1 can be released from activated cells in an inflammatory en-
vironment; second, in SLE, apoptotic cells are not cleared properly because of impaired
phagocytosis, which can lead to necrotic cells, which in turn release HMGB1; third, in SLE,
low-density granulocytes are present that can spontaneously form NET (neutrophil extra-
cellular traps), a process that leads to externalization of cellular content including
HMGB1. In circulation or at inflammatory sites, HMGB1 can form complexes with DNA, nu-
cleosomes, LPS or cytokines. HMGB1 alone or in complex can induce inflammation, for in-
stance, in the kidney or in the skin of lupus patients (4), which in turn can lead to produc-
tion of inflammatory cytokines. Also, complexed HMGB1 can activate plasmacytoid
dendritic cells to produce IFN-α (5), a driving cytokine in lupus pathogenesis. Lastly, com-
plexed HMGB1 can stimulate B-cells to produce autoantibodies (6). These activations
lead to an inflammatory loop in which cytokines activate other cells, autoantibodies play
a role in NETosis and HMGB1 itself can also induce NETosis and can play a role in the im-
paired phagocytosis. , HMGB1; , IFN-α; , inflammatory cytokines. 
7 8 |  S C H A P E R E T  A L .  |  M O L  M E D  2 0 : 7 2 - 7 9 ,  2 0 1 4
H M G B 1  I N  S Y S T E M I C  L U P U S  E R Y T H E M A T O S U S
3. Sanford AN, Dietzmann K, Sullivan KE. (2005)
Apoptotic cells, autoantibodies, and the role of
HMGB1 in the subcellular localization of an au-
toantigen. J. Autoimmun. 25:264–71.
4. Perniok A, Wedekind F, Herrmann M, Specker C,
Schneider M. (1998) High levels of circulating
early apoptic peripheral blood mononuclear cells
in systemic lupus erythematosus. Lupus. 7:113–8.
5. Courtney PA, et al. (1999) Increased apoptotic pe-
ripheral blood neutrophils in systemic lupus ery-
thematosus: relations with disease activity, anti-
bodies to double stranded DNA, and
neutropenia. Ann. Rheum. Dis. 58:309–14.
6. Baumann I, et al. (2002) Impaired uptake of
apoptotic cells into tingible body macrophages in
germinal centers of patients with systemic lupus
erythematosus. Arthritis Rheum. 46:191–201.
7. Reefman E, et al. (2006) Is disturbed clearance of
apoptotic keratinocytes responsible for UVB-
 induced inflammatory skin lesions in systemic
lupus erythematosus? Arthritis Res. Ther. 8:R156.
8. Urbonaviciute V, et al. (2008) Induction of inflam-
matory and immune responses by HMGB1-
 nucleosome complexes: implications for the
pathogenesis of SLE. J. Exp. Med. 205:3007–18.
9. Bianchi ME, Agresti A. (2005) HMG proteins: dy-
namic players in gene regulation and differentia-
tion. Curr. Opin. Genet. Dev. 15:496–506.
10. Calogero S, et al. (1999) The lack of chromosomal
protein Hmg1 does not disrupt cell growth but
causes lethal hypoglycaemia in newborn mice.
Nat. Genet. 22:276–80.
11. Kazama H, et al. (2008) Induction of immunologi-
cal tolerance by apoptotic cells requires caspase-
dependent oxidation of high-mobility group box-
1 protein. Immunity. 29:21–32.
12. Scaffidi P, Misteli T, Bianchi ME. (2002) Release
of chromatin protein HMGB1 by necrotic cells
triggers inflammation. Nature. 418:191–5.
13. Andersson U, et al. (2000) High mobility group 1
protein (HMG-1) stimulates proinflammatory cy-
tokine synthesis in human monocytes. J. Exp.
Med. 192:565–70.
14. Youn JH, Oh YJ, Kim ES, Choi JE, Shin J. (2008)
High mobility group box 1 protein binding to
lipopolysaccharide facilitates transfer of
lipopolysaccharide to CD14 and enhances
lipopolysaccharide-mediated TNF-α production
in human monocytes. 180:5067–74.
15. Wang H, et al. (1999) HMG-1 as a late mediator of
endotoxin lethality in mice. Science. 285:248–51.
16. Hreggvidsdottir HS, et al. (2009) The alarmin
HMGB1 acts in synergy with endogenous and
exogenous danger signals to promote inflamma-
tion. J. Leukoc. Biol. 86:655–62.
17. Schiraldi M, et al. (2012) HMGB1 promotes re-
cruitment of inflammatory cells to damaged tis-
sues by forming a complex with CXCL12 and
signaling via CXCR4. J. Exp. Med. 209:551–63.
18. Straino S, et al. (2008) High-mobility group box 1
protein in human and murine skin: involvement
in wound healing. J. Invest. Dermatol. 128:1545–53.
19. Mitola S, et al. (2006) Cutting edge: extracellular
high mobility group box-1 protein is a proangio-
genic cytokine. J. Immunol. 176:12–5.
20. Van Zoelen MAD, et al. (2009) Role of toll-like re-
ceptors 2 and 4, and the receptor for advanced gly-
cation end products in high-mobility group box 1-
induced inflammation in vivo. Shock. 31:280–4.
21. Park JS, et al. (2004) Involvement of toll-like recep-
tors 2 and 4 in cellular activation by high mobility
group box 1 protein. J. Biol. Chem. 279:7370–7.
22. Kokkola R, et al. (2005) RAGE is the major recep-
tor for the proinflammatory activity of HMGB1
in rodent macrophages. Scand. J. Immunol. 61:1–9.
23. Palumbo R, et al. (2009) Src family kinases are
necessary for cell migration induced by extracel-
lular HMGB1. J. Leukoc. Biol. 86:617–23.
24. Palumbo R, et al. (2007) Cells migrating to sites of
tissue damage in response to the danger signal
HMGB1 require NF-kappaB activation. J. Cell.
Biol. 179:33–40.
25. Venereau E, et al. (2012) Mutually exclusive redox
forms of HMGB1 promote cell recruitment or
proinflammatory cytokine release. J. Exp. Med.
209:1519–28.
26. Yang H, et al. (2010) A critical cysteine is required
for HMGB1 binding to toll-like receptor 4 and ac-
tivation of macrophage cytokine release. Proc.
Natl. Acad. Sci. U. S. A. 107:11942–7.
27. Yang H, et al. (2012) Redox modification of cys-
teine residues regulates the cytokine activity of
high mobility group box-1 (HMGB1). Mol. Med.
18:250–9.
28. Hreggvidsdottir HS, et al. (2012) High mobility
group box protein 1 (HMGB1)-partner molecule
complexes enhance cytokine production by sig-
naling through the partner molecule receptor.
Mol. Med. 18:224–30.
29. Tian J, et al. (2007) Toll-like receptor 9-dependent
activation by DNA-containing immune com-
plexes is mediated by HMGB1 and RAGE. Nat.
Immunol. 8:487–96.
30. Urbonaviciute V, et al. (2007) HMGB1-containing
nucleosomes released from secondary necrotic
cells cause activation and cytokine release from
monocytes/macrophages and dendritic cells: im-
plications for the immunopathogenesis of SLE.
Ann. Rheum. Dis. 66:A11.
31. Wen Z, et al. (2013) Autoantibody induction by
DNA-containing immune complexes requires
HMGB1 with the TLR2/microRNA-155 pathway.
J. Immunol. 190:5411–22.
32. Qing X, et al. (2008) Pathogenic anti-DNA antibod-
ies modulate gene expression in mesangial cells:
involvement of HMGB1 in anti-DNA antibody-in-
duced renal injury. Immunol. Lett. 121:61–73.
33. Sun W, et al. (2013) Immune complexes activate
human endothelium involving the cell-signaling
HMGB1-RAGE axis in the pathogenesis of lupus
vasculitis. Lab. Invest. 93:626–38.
34. Munoz LE, et al. (2008) Apoptosis in the patho-
genesis of systemic lupus erythematosus. Lupus.
17:371–5.
35. Bijl M, Reefman E, Horst G, Limburg PC, Kallen-
berg CG. (2006) Reduced uptake of apoptotic
cells by macrophages in systemic lupus erythe-
matosus: correlates with decreased serum levels
of complement. Ann. Rheum. Dis. 65:57–63.
36. Liu G, et al. (2008) High mobility group protein-1
inhibits phagocytosis of apoptotic neutrophils
through binding to phosphatidylserine. J. Im-
munol. 181:4240–6.
37. Friggeri A, et al. (2010) HMGB1 inhibits macro-
phage activity in efferocytosis through binding to
the alphavbeta3-integrin. Am. J. Physiol. Cell.
Physiol. 299:C1267–76.
38. Banerjee S, Friggeri A, Liu G, Abraham E. (2010)
The C-terminal acidic tail is responsible for the
inhibitory effects of HMGB1 on efferocytosis. 
J. Leukoc. Biol. 88:973–9.
39. Davis K, et al. (2012) Poly(ADP-ribosyl)ation of high
mobility group box 1 (HMGB1) protein enhances
inhibition of efferocytosis. Mol. Med. 18:359–69.
40. Banerjee S, et al. (2011) Intracellular HMGB1
negatively regulates efferocytosis. J. Immunol.
187:4686–94.
41. Brinkmann V, et al. (2004) Neutrophil extracellu-
lar traps kill bacteria. Science. 303:1532–5.
42. Brinkmann V, Laube B, Abu Abed U, Goosmann
C, Zychlinsky A. (2010) Neutrophil extracellular
traps: how to generate and visualize them. J. Vis.
Exp. (36):e1724.
43. Kessenbrock K, et al. (2009) Netting neutrophils
in autoimmune small-vessel vasculitis. Nat. Med.
15:623–5.
44. Garcia-Romo GS, et al. (2011) Netting neutrophils
are major inducers of type I IFN production in
pediatric systemic lupus erythematosus. Sci.
Transl. Med. 3:73ra20.
45. Lande R, et al. (2011) Neutrophils activate plas-
macytoid dendritic cells by releasing self-DNA-
peptide complexes in systemic lupus erythe-
matosus. Sci. Transl. Med. 3:73ra19.
46. Villanueva E, et al. (2011) Netting neutrophils in-
duce endothelial damage, infiltrate tissues, and
expose immunostimulatory molecules in systemic
lupus erythematosus. J. Immunol. 187:538–52.
47. Leffler J, et al. (2013) Degradation of neutrophil
extracellular traps co-varies with disease activity
in patients with systemic lupus erythematosus.
Arthritis Res. Ther. 15:R84.
48. Carmona-Rivera C, Kaplan MJ. (2013) Low-
 density granulocytes: a distinct class of neu-
trophils in systemic autoimmunity. Semin. Im-
munopathol. 35:455–63.
49. Tadie JM, et al. (2013) HMGB1 promotes neu-
trophil extracellular trap formation through in-
teractions with Toll-like receptor 4. Am. J. Physiol.
Lung Cell. Mol. Physiol. 304:L342–9.
50. Abdulahad DA, et al. (2011) High mobility group
box 1 (HMGB1) and anti-HMGB1 antibodies and
their relation to disease characteristics in sys-
temic lupus erythematosus. Arthritis Res. Ther.
13:R71.
51. Jiang W, Pisetsky DS. (2008) Expression of high
mobility group protein 1 in the sera of patients
and mice with systemic lupus erythematosus.
Ann. Rheum. Dis. 67:727–8.
R E V I E W  A R T I C L E
M O L  M E D  2 0 : 7 2 - 7 9 ,  2 0 1 4  |  S C H A P E R E T  A L .  |  7 9
52. Li J, et al. (2010) Expression of high mobility
group box chromosomal protein 1 and its modu-
lating effects on downstream cytokines in sys-
temic lupus erythematosus. J. Rheumatol.
37:766–75.
53. Ma C, et al. (2012) Elevated plasma level of
HMGB1 is associated with disease activity and
combined alterations with IFN-alpha and TNF-
alpha in systemic lupus erythematosus. Rheuma-
tol. Int. 32:395–402.
54. Zickert A, et al. (2012) Renal expression and
serum levels of high mobility group box 1 pro-
tein in lupus nephritis. Arthritis Res. Ther. 14:R36.
55. Abdulahad DA, et al. (2012) Urine levels of
HMGB1 in systemic lupus erythematosus pa-
tients with and without renal manifestations.
Arthritis Res. Ther. 14:R184.
56. Hayashi A, et al. (2009) Lupus antibodies to the
HMGB1 chromosomal protein: epitope mapping
and association with disease activity. Mod.
Rheumatol. 19:283–92.
57. de Souza AW, et al. (2013) Is serum HMGB1 a
biomarker in ANCA-associated vasculitis?
Arthritis Res. Ther. 15:R104.
58. Urbonaviciute V, et al. (2007) Factors masking
HMGB1 in human serum and plasma. J. Leukoc.
Biol. 81:67–74.
59. Barnay-Verdier S, et al. (2011) Emergence of au-
toantibodies to HMGB1 is associated with sur-
vival in patients with septic shock. Intensive Care
Med. 37:957–62.
60. Schaper F, Heeringa P, Bijl M, Westra J. (2013) In-
hibition of high-mobility group box 1 as thera-
peutic option in autoimmune disease: lessons
from animal models. Curr. Opin. Rheumatol.
25:254–9.
61. Dupire G, Nicaise C, Gangji V, Soyfoo MS. (2012)
Increased serum levels of high-mobility group
box 1 (HMGB1) in primary Sjögren’s syndrome.
Scand. J. Rheumatol. 41:120–3.
62. Goldstein RS, et al. (2007) Cholinergic anti-in-
flammatory pathway activity and high mobility
group box-1 (HMGB1) serum levels in patients
with rheumatoid arthritis. Mol. Med. 13:210–5.
63. Pullerits R, Urbonaviciute V, Voll RE, Forsblad-
D’Elia H, Carlsten H. (2011) Serum levels of
HMGB1 in postmenopausal patients with
rheumatoid arthritis: associations with proinflam-
matory cytokines, acute-phase reactants, and clini-
cal disease characteristics. J. Rheumatol. 38:1523–5.
64. Schierbeck H, et al. (2013) HMGB1 levels are in-
creased in patients with juvenile idiopathic arthri-
tis, correlate with early onset of disease, and are
independent of disease duration. J. Rheumatol.
40:1604–13.
65. Taniguchi N, et al. (2003) High mobility group
box chromosomal protein 1 plays a role in the
pathogenesis of rheumatoid arthritis as a novel
cytokine. Arthritis Rheum. 48:971–81.
66. Wibisono D, et al. (2010) Serum HMGB1 levels
are increased in active Wegener’s granulomatosis
and differentiate between active forms of ANCA-
associated vasculitis. Ann. Rheum. Dis. 69:1888–9.
67. Bruchfeld A, et al. (2011) High-mobility group
box-1 protein (HMGB1) is increased in antineu-
trophilic cytoplasmatic antibody (ANCA)-
 associated vasculitis with renal manifestations.
Mol. Med. 17:29–35.
68. Henes FO, et al. (2011) Correlation of serum level
of high mobility group box 1 with the burden of
granulomatous inflammation in granulomatosis
with polyangiitis (Wegener’s). Ann. Rheum. Dis.
70:1926–9.
69. Oktayoglu P, et al. (2013) Elevated serum levels
of high mobility group box protein 1 (HMGB1)
in patients with ankylosing spondylitis and its
association with disease activity and quality of
life. Rheumatol. Int. 33:1327–31.
70. Kanakoudi-Tsakalidou F, et al. (2014) Simultane-
ous changes in serum HMGB1 and IFN-α levels
and in LAIR-1 expression on plasmatoid den-
dritic cells of patients with juvenile SLE. New
therapeutic options? Lupus. 23:305–12.
71. Urbonaviciute V, et al. (2009) Oxidation of the
alarmin high-mobility group box 1 protein
(HMGB1) during apoptosis. Autoimmunity.
42:305–7.
72. Kuhn A, Bijl M. (2008) Pathogenesis of cutaneous
lupus erythematosus. Lupus. 17:389–93.
73. Popovic K, et al. (2005) Increased expression of
the novel proinflammatory cytokine high mobil-
ity group box chromosomal protein 1 in skin le-
sions of patients with lupus erythematosus.
Arthritis Rheum. 52:3639–45.
74. Barkauskaite V, et al. (2007) Translocation of the
novel cytokine HMGB1 to the cytoplasm and ex-
tracellular space coincides with the peak of clinical
activity in experimentally UV-induced lesions of
cutaneous lupus erythematosus. Lupus. 16:794–802.
75. Abdulahad DA, et al. (2013) High mobility group
box 1 (HMGB1) in relation to cutaneous inflam-
mation in systemic lupus erythematosus (SLE).
Lupus. 22:597–606.
